Dysregulation of GDNF and GFRα1 expression in multifactorial Hirschsprung disease Authors: Gunadi, Setiani Silvy Nurhidayah, Aleyy Adany, Farah Shahnaz Pravinovia, Siti Maisaroh, Kurnia Corie Tonda, Pramana Adhityo, Estelita Liana, Kristy Iskandar, Andi Dwihantoro Published: 2026 ABSTRACT ObjectiveHSCR is caused by disruption of complex signaling pathways within the gene regulatory network (GRN) during enteric nervous system (ENS) development, including glial cell line-derived neurotrophic factor (GDNF) and GDNF family receptor alpha-1 (GFRα1). However, pathogenic variants in all GRN genes account for only ~ 80% cases; therefore, the epigenetic role remains to be elucidated. We compared GDNF and GFRα1 expression between HSCR patients and controls.ResultsqPCR revealed an upregulated GDNF expression in both ganglionic (206.37-fold) and aganglionic (126.35-fold) HSCR compared to control colons (ΔCT 7.65 ± 2.19 vs. 15.34 ± 1.34; p = 0.0001; and ΔCT 8.35 ± 2.57 vs. 15.34 ± 1.34; p = 0.0001). qPCR also showed an upregulated GFRα1 expression in both ganglionic (29.66-fold) and aganglionic (18.44-fold) HSCR compared to control colons (ΔCT 8.44 ± 1.98 vs. 13.33 ± 1.36; p = 0.0001; and ΔCT 9.13 ± 1.46 vs. 13.33 ± 1.36; p = 0.0001). In addition, no significant differences were observed between ganglionic and aganglionic segments for either GDNF or GFRα1 (ΔCT 7.65 ± 2.19 vs. 8.35 ± 2.57; p = 0.43; and ΔCT 8.44 ± 1.98 vs. 9.13 ± 1.46; p = 0.29). Our study demonstrates global aberrant expression of GDNF and GFRα1 in HSCR patients. These findings underscore the complexity of HSCR as a multifactorial disorder and highlight the importance of integrated signaling networks in ENS development, providing a rationale for further mechanistic and translational studies.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s13104-026-07912-5. Introduction Hirschsprung disease (HSCR) is characterized by the absence of ganglion cells in the ganglion plexuses of the gut [1]. The enteric nervous system (ENS) covers the digestive tract and regulates bowel movements and epithelial activity in response to external inputs. From neural crest-derived progenitors, interconnected enteric ganglia with neurons and glia are formed before birth. HSCR affects 1 in 5000 babies due to incomplete colonization of the distal colon by these ENS progenitors. The aganglionic colon, or distal colon without ganglia, remains tonically constricted in HSCR, resulting in functional obstruction [2]. Numerous genes contribute to HSCR development [2]. REarranged during Transfection (RET), a transmembrane receptor tyrosine kinase activated by glial cell-derived neurotrophic factor (GDNF) binding to the coreceptor GDNF family receptor-1 (GFRα1), is the primary gene associated with HSCR. ENS progenitors require GDNF-GFRα1-RET signaling to survive, proliferate, and migrate [2, 3]. The ability of GDNF to extend the survival of midbrain dopaminergic neurons, along with its status as a distant relative of the TGF superfamily, helped establish its identity. The growth and maintenance of homeostasis in the ENS neurons depend on the GDNF family ligands (GFLs), including neurturin, artemin, and persephin [3]. The growth and maintenance of ganglion cells depend mainly on GDNF-GFRα-RET signaling [4]. Pathogenic variants, including those in GDNF and RET genes, can disrupt this signaling system, leading to HSCR [5]. However, pathogenic variants in all gene regulatory networks account for only ~ 80% of HSCR cases [6]; therefore, the epigenetic role remains to be elucidated [7]. This study determined and compared GDNF and GFRα1 expression between HSCR patients and controls. Material and methods Study participants This was an analytic observational study involving 30 HSCR patients and 30 control subjects at our hospital. HSCR diagnosis was established based on rectal biopsy (Fig. 1) [5]. HSCR colon tissues, including both aganglionic and ganglionic segments, were obtained during pull-through surgery. Control colon tissues were collected from patients with anorectal malformations undergoing definitive surgical procedures, who showed no clinical evidence of ENS dysfunction, and were not age-matched.Fig. 1a Calretinin showed no ganglion cells in suspicion of Hirschsprung disease (× 400). b S100 immunohistochemistry showed hypertrophy of nerve trunk in suspicious HSCR (× 400) a Calretinin showed no ganglion cells in suspicion of Hirschsprung disease (× 400). b S100 immunohistochemistry showed hypertrophy of nerve trunk in suspicious HSCR (× 400) Ethical approval for this study was obtained from the Institutional Review Board of our institution (KE/0256/03/2022). The subjects were recruited using consecutive sampling among patients who agreed to participate in the study and signed a consent form. Total RNA isolation Total RNA was isolated from colon samples of both aganglionic and ganglionic HSCR patients and control subjects using a Total RNA Mini Kit (Tissue) (Geneaid Biotech Ltd., New Taipei City, Taiwan) and stored at −80 °C until use. Total RNA quality and concentration were measured before analysis using a NanoDrop 2000 Spectrophotometer (Thermo Scientific, Wilmington, DE, USA). The OD260/280 ratio usually falls between 1.8 and 2.0, indicating high RNA purity. Quantitative real-time polymerase chain reaction (qPCR) One-step quantitative qPCR was performed using Kapa SYBR Fast qRT-PCR One Step Kit Universal (Kapa Biosystems, Massachusetts, USA), and BioRad CFX Real-Time PCR System (California, USA). The GDNF and GFRα1 primers used were as follows [8]: GDNF (forward): 5’-ACCTGGAGTTAATGTCCAACC-3’; GDNF (reverse): 5’-GGCATATTTGAGTCACTGCT-3’; GFRα1 (forward): 5’-AGGGAAATGATCTGCTGGAGGA-3’; and GFRα1 (reverse): 5’-CTCTGGCTGGCAGTTGGTAAAA-3’. Gene expression was normalized to GAPDH using the following primers [9]: 5′-GCACCGTCAAGGCTGAGAAC-3′ (forward) and 5′-TGGTGAAGACCGCCAGTGGA-3′ (reverse). All qPCRs were performed in duplicate, and the average CT value of the two replicates was used for analysis. Statistical analysis GDNF and GFRα1 expressions were analyzed using the Livak (2−ΔΔCT) method. CT values were reported as mean ± SD. ΔCT was calculated by normalizing target gene expression to GAPDH. ΔΔCT was calculated relative to the mean ΔCT of the control group, and fold change was determined using the 2−ΔΔCT formula. Differences between the ganglionic and aganglionic colon, as well as between the HSCR and control groups, were analyzed with an independent t-test. Results qPCR revealed an upregulated GDNF expression in both ganglionic (206.37-fold) and aganglionic (126.35-fold) HSCR compared to control colons (ΔCT 7.65 ± 2.19 vs. 15.34 ± 1.34; p = 0.0001; and ΔCT 8.35 ± 2.57 vs. 15.34 ± 1.34; p = 0.0001) (Table 1).Table 1GDNF expression between HSCR patients and controlsGDNFΔCT ± SDΔΔCTFold changep-valueGanglionic colon7.65 ± 2.19 − 7.69206.370.0001*Aganglionic colon8.35 ± 2.57 − 6.99126.350.0001*Control15.34 ± 1.34*p-value < 0.05 is considered significant Table 1GDNF expression between HSCR patients and controlsGDNFΔCT ± SDΔΔCTFold changep-valueGanglionic colon7.65 ± 2.19 − 7.69206.370.0001*Aganglionic colon8.35 ± 2.57 − 6.99126.350.0001*Control15.34 ± 1.34*p-value < 0.05 is considered significant GDNF expression between HSCR patients and controls *p-value < 0.05 is considered significant qPCR also showed an upregulated GFRα1 expression in both ganglionic (29.66-fold) and aganglionic (18.44-fold) HSCR compared to control colons (ΔCT 8.44 ± 1.98 vs. 13.33 ± 1.36; p = 0.0001; and ΔCT 9.13 ± 1.46 vs. 13.33 ± 1.36; p = 0.0001) (Table 2).Table 2GFRα1 expression between HSCR patients and controlsGFRα1ΔCT ± SDΔΔCTFold changep-valueGanglionic Colon8.44 ± 1.98 − 4.8929.660.0001*Aganglionic Colon9.13 ± 1.46 − 4.218.440.0001*Control13.33 ± 1.36*p-value < 0.05 is considered significant Table 2GFRα1 expression between HSCR patients and controlsGFRα1ΔCT ± SDΔΔCTFold changep-valueGanglionic Colon8.44 ± 1.98 − 4.8929.660.0001*Aganglionic Colon9.13 ± 1.46 − 4.218.440.0001*Control13.33 ± 1.36*p-value < 0.05 is considered significant GFRα1 expression between HSCR patients and controls *p-value < 0.05 is considered significant Additionally, GDNF expression did not differ significantly between ganglionic and aganglionic segments (ΔCT 7.65 ± 2.19 vs. 8.35 ± 2.57; p = 0.4288). Similarly, GFRα1 expression showed similar levels between segments (ΔCT 8.44 ± 1.98 vs. 9.13 ± 1.46; p = 0.2866) (Supplementary Table 1). Discussion Our study shows aberrant GDNF and GFRα1 expression in patients with HSCR. It is similar to a previous report [10]. However, we provide new evidence of aberrant GDNF expressions in children with HSCR from a particular population (Indonesia [this study] vs. Caucasian [10]). In addition, our study also shows aberrant GFRα1 expression in HSCR patients. A previous study found different GFRα1 expression levels among HSCR cases [8]. For the first time, we provided both GDNF and GFRα1 expression data from the same patient cohort. The cause of HSCR is multifactorial. Given the complex etiology of HSCR, 80% of known cases are caused by pathogenic variants in genes including RET, EDN3, EDNRB, GDNF, and NRTN [6]. Patients with HSCR who underwent GFRα1 screening did not find any pathogenic variants. This shows that GFRα1 pathogenic variants are not a common cause of HSCR. However, GDNF germline variants may interact with RET and other HSCR susceptibility loci to modify the phenotype [5]. This suggests that GDNF signaling is essential for the ENS’s proper function. The lack of association between GFRα1 variants and HSCR may underscore the functional redundancy and cross-talk between these GFRα coreceptors and GFLs [5, 11]. Abnormal expression patterns of both GDNF and GFRα1 underscore the complexity of ENS development. The observed upregulation may represent a compensatory response rather than a direct pathogenic mechanism. These findings support the concept that HSCR is not solely driven by pathogenic variants in individual genes but rather involves dysregulation within interconnected signaling pathways, consistent with its classification as a multifactorial complex genetic disorder. Moreover, variations in GDNF and GFRα1 expression levels may contribute to the heterogeneity in clinical presentation, disease severity, and functional outcomes among patients. Furthermore, the comparison between ganglionic and aganglionic segments showed no significant differences in GDNF and GFRα1 expression. This suggests that the upregulation is not region-specific and likely reflects a global change in the GDNF–GFRα1 signaling pathway in HSCR. These findings support earlier research. Lui et al. found that GFRα1, GFRα2, and GFRα3 levels were similar across the two segment types, with only a few cases showing downregulation [8]. Additionally, transcriptomic studies indicate no significant gene expression differences outside the myenteric plexus among various intestinal layers, including epithelium, submucosa, and muscle, between ganglionic and aganglionic regions [12]. Overall, these findings suggest that the dysregulation of key signaling pathways in HSCR may affect broader tissue areas rather than being confined to aganglionic regions. However, our findings should be interpreted with caution. First, the present study examined transcriptional regulation of GDNF and GFRα1 exclusively at the mRNA level. Whether the observed upregulation translates into corresponding changes in protein abundance, receptor function, or downstream RET-mediated signaling activity remains to be determined. Further protein-level validation through approaches such as Western blotting or immunohistochemistry is required to draw causal conclusions regarding the GDNF–GFRα1 function. Second, the control group was not fully age-matched to the HSCR cohort. Previous research indicates that genes related to the enteric nervous system may exhibit age-dependent transcriptional changes during intestinal development and maturation [13]. Thus, the differences observed in GDNF and GFRα1 expression might partly result from age-related variation. Despite this, both ganglionic and aganglionic segments from HSCR patients in our study consistently showed increased GDNF and GFRα1 expression compared to controls, implying that these changes are more likely linked to HSCR-specific molecular dysregulation rather than age alone. Further studies with age-matched controls and larger multicenter cohorts are needed to confirm these results and determine the precise role of age in GDNF–GFRα1 signaling in HSCR development. In ENS, the GDNF family is essential for the growth and survival of neurons. The four GFLs: GDNF, neurturin, artemin, and persephin have all been identified. The GFLs communicate through a sophisticated multicomponent receptor. A coreceptor GFRα (GFRα1-GFRα4) membrane-bound by glycosylphosphatidylinositol and RET on the cell membrane make up this complex. Each GFL has a particular GFRα coreceptor that it binds to most strongly to trigger RET. GDNF-GFRα1, NTRN-GFRα2, artemin-GFRα3, and persephin-GFRα4 had the highest affinities. Dimerization of RET and activation of the RET kinase domain occur upon binding of GFL to its GFRα, forming a GFL-GFRα1-RET complex. Cis signaling refers to the formation of this ligand-receptor complex between molecules in the same cell. It was shown that the soluble form of GFRα1 secreted by gut mesenchyme cells might enhance GDNF’s induction effect on the survival and proliferation of neurons. Trans-signaling in the adult rat central nervous system has been proposed as an alternative. This entails interactions between GDNF-GFRα1 and RET on two distinct cells nearby [5, 14]. Interestingly, a recent study found that administering GDNF to HSCR mice shortly after birth can permanently generate a new ENS from tissue-resident neural progenitors. This process is mediated by NCAM1 rather than by its usual signaling receptor, RET [15]. GDNF stimulated new neurogenesis in human HSCR colonic explants collected during pull-through and cultured in vitro, indicating that the ENS-inducing effect of GDNF is partly attributable to its ability to mobilize Schwann cell precursors from external nerves and promote their differentiation into enteric neurons and glia [2, 16]. Conclusions Our study demonstrates global aberrant expression of GDNF and GFRα1 in patients with HSCR. These findings underscore the complexity of HSCR as a multifactorial disorder and highlight the importance of integrated signaling networks in ENS development, providing a rationale for further mechanistic and translational studies. Limitations Several limitations of this study should be acknowledged. First, the sample size was relatively small and derived from a single institution, which may limit generalizability. Second, we did not perform protein-level or functional assays, so it remains unclear whether the observed mRNA upregulation of GDNF and GFRα1 leads to corresponding changes in protein expression or downstream signaling. Third, the control group was not fully age-matched to the HSCR cohort, and age-related differences in enteric nervous system gene expression may have influenced the transcriptional profiles observed. Future studies with larger, multicenter, age-matched cohorts and integrated protein-level and functional analyses are needed to address these issues. Supplementary Information Supplementary Material 1. Supplementary Material 1.